Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company is headquartered in Bedminster, New Jersey and currently employs 15 full-time employees. The firm focuses on identifying and developing novel pharmaceutical products. The firm's technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, which is designed to make safer, more tolerable, less toxic and orally bioavailable. The firm's technology combines the use of lipids as active pharmaceutical ingredients (APIs) and the use of lipids in cochleate-shaped lipid-crystal nano-particle drug delivery vehicles. The Company’s product candidates include, MAT2203 and MAT2501.The Company's anti-infective product candidate, MAT 2203, is an application of its cochleate delivery technology to a spectrum anti-fungal drug called amphotericin B. The firm's MAT2501 is an orally administered, encochleated formulation of the spectrum IV-only aminoglycoside antibiotic agent amikacin, utilizes the Company's lipid-crystal, nanoparticle delivery technology.
What is Matinas Biopharma Holdings's quote symbol?
What is the 52 week high and low for Matinas Biopharma Holdings (NYSEMKT: MTNB)?
How much is Matinas Biopharma Holdings stock worth today?
How much is Matinas Biopharma Holdings's stock price per share?
What is Matinas Biopharma Holdings's Market Cap?